Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00284830 · ClinicalTrials.gov registry record · NA
SAVEPACe - Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction
A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- NA
- Development phase
- 1,070
- Enrollment target
NCT00284830: Completed NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT00284830 is a NA study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 1,070 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00284830, a NA study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,070 participants
- Enrollment target
Study Summary
SAVE PACe is a large, prospective, single-blinded, randomized clinical trial with the main objective to study the effect of unnecessary right ventricular apical pacing on the clinical outcome of time to development of persistent AF.
Interventions
- DEVICE Implantable Pulse Generators
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,070 participants |
| Start Date | 2003-01 |
| Est. Completion | 2008-02 |
| Phase | NA |
What the finished NCT00284830 record still lists
NCT00284830 is an interventional study that assigns participants to a tested intervention. Its 1,070 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 1 intervention - of which Implantable Pulse Generators is the first listed.
NCT00284830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00284830 about?
NCT00284830 is a clinical study titled "SAVEPACe - Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction". SAVE PACe is a large, prospective, single-blinded, randomized clinical trial with the main objective to study the effect of unnecessary right ventricular apical pacing on the clinical outcome of time to development of persistent AF.
What is the current status of trial NCT00284830?
This trial is currently completed. It is a NA study. The enrollment target is 1,070 participants. The study started on 2003-01. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00284830?
The interventions under investigation include: Implantable Pulse Generators (DEVICE).
Who is sponsoring clinical trial NCT00284830?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00284830's enrollment target sits among peer trials
1,070 97th of 2000 higher than 1,904 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
- NCT06159673 · 1,074 participants · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
- NCT04165798 · 1,065 participants
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia